Camrelizumab, apatinib, nab-paclitaxel, and S-1 in combination for the conversion therapy of advanced gastric cancer
10.3760/cma.j.cn115396-20220214-00048
- VernacularTitle:卡瑞利珠单抗联合阿帕替尼、白蛋白紫杉醇及替吉奥用于进展期胃癌的转化治疗
- Author:
Wei DENG
1
;
Yiqiao ZHANG
;
Chao JING
;
Xiaobao YANG
;
Zhigang BAI
;
Jun ZHANG
Author Information
1. 首都医科大学附属北京友谊医院普外科，北京 100050
- Keywords:
Stomach neoplasms;
Therapeutic uses;
Immunosuppressive agents;
Conversion therapy;
Chemotherapy;
Targeted therapy
- From:
International Journal of Surgery
2022;49(4):242-247,F4
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and safety of the combination therapy of camrelizumab, apatinib, nab-paclitaxel, and S-1 for patients with locally unresectable advanced gastric cancer.Methods:From September 1, 2019 to August 1, 2021, in Beijing Friendship Hospital Affiliated to Capital Medical University, 17 patients with advanced gastric cancer were enrolled in this prospective, single-arm study. All the enrolled patients received camrelizumab, nab-paclitaxel, apatinib and S-1 combination therapy (in each 21 days cycle, camrelizumab 200 mg intravenously, D1; nab-paclitaxel 240 mg/m 2 intravenously, D2; apatinib 500 mg orally, once a day, D1-D21; S-1 40-60 mg twice a day, D1-D14). Patients who have been evaluated by multidisciplinary team to be eligible for radical surgery should stop treatment for at least 2 weeks. Patients were discontinued from the study when disease progression or unbearable toxicity, or withdrew consent. We analyzed the conversion rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.Statistical data were show by numbers and persentages(%), and comparisons between subgroups were assessed by Fisher′s exact probability method. Patients survival was analyzed using Kaplan-Meier curves and compared between groups using Log-rank. Results:At the data of cutoff (December 15, 2021), the median follow-up duration was 19.6 months. Eight of 17 patients underwent gastrectomy, and all of them were R0 resection (47.1%, 95% CI: 0.262-0.690). ORR was 47.1%, DCR was 82.4%, the median overall survival was 23.63 months. Grade 3 and 4 adverse events occurred in 3 patients (17.6%), including neutropenia, thrombocytopenia, anemia and upper gastrointestinal hemorrhage. There were no serious treatment-related adverse events or treatment-related deaths. Conclusion:In this trial, the combination of camrelizumab, apatinib, nab-paclitaxel and S-1 as the conversion therapy showed significant anti-tumor activity and manageable adverse events, providing a new option for locally unresectable advanced gastric cancer.
